Clinical Trial Detail

NCT ID NCT03433469
Title Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: senior adult

No variant requirements are available.